Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids

被引:6
作者
Ng, X. [1 ]
dosReis, S. [1 ]
Beardsley, R. [1 ]
Magder, L. [2 ]
Mullins, C. D. [1 ]
Petri, M. [3 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, 220 Arch St,12th Floor, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA
[3] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD USA
基金
美国医疗保健研究与质量局;
关键词
Corticosteroids; patients'; perceptions; systemic lupus erythematosus; QUALITY-OF-LIFE; DISEASE-ACTIVITY; HEALTH-STATUS; CLINICAL-TRIALS; ORGAN DAMAGE; DISCORDANCE; PHYSICIANS; EPIDEMIOLOGY; PERSPECTIVE; PREDNISONE;
D O I
10.1177/0961203317726375
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The use of corticosteroids in systemic lupus erythematosus (SLE) patients requires difficult trade-offs between efficacy and risk of toxicity. This qualitative study examined SLE patients' most desired outcomes and their concerns with corticosteroid use in SLE treatment. Methods SLE patients with current/past experience with using corticosteroids were recruited from the clinics at the Johns Hopkins Lupus Center and the University of Maryland Medical Center. Five in-depth interviews (N=5) and four focus groups (N=15) were conducted during which discussions were transcribed and analyzed based on a grounded theory approach. Results We identified five major themes describing SLE patients' most desired outcomes: reduction in flares, maintenance of normal activities, minimization of treatment side effects, prevention of future organ damage, and finding a cure. Further, SLE patients reported these primary concerns with the adverse effects of corticosteroids: weight gain, organ damage (particularly bone-related damage), mood swings/irritability, sleep disturbances, and dental issues. Patients appeared to be more concerned with adverse effects that immediately affected their day-to-day lives. Conclusion Knowledge gained during this study better informs how patients view the benefits and risks of corticosteroids. This can facilitate discussions between physicians and patients as they work together to determine the appropriate use of corticosteroids.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 39 条
[1]   Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus - the Hopkins Lupus Cohort [J].
Al Sawah, Sarah ;
Zhang, Xiang ;
Zhu, Baojin ;
Magder, Laurence S. ;
Foster, Shonda A. ;
Iikuni, Noriko ;
Petri, Michelle .
LUPUS SCIENCE & MEDICINE, 2015, 2 (01)
[2]   Systemic lupus erythematosus in three ethnic groups.: XI.: Sources of discrepancy in perception of disease activity:: A comparison of physician and patient visual analog scale scores [J].
Alarcón, GS ;
McGwin, G ;
Brooks, K ;
Roseman, JM ;
Fessler, BJ ;
Sanchez, ML ;
Bastian, HM ;
Friedman, AW ;
Baethge, BA ;
Reveille, JD .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (04) :408-413
[3]   Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: A comparison with Wegener's granulomatosis [J].
Boomsma, MM ;
Bijl, M ;
Stegeman, CA ;
Kallenberg, CGM ;
Hoffman, GS ;
Tervaert, JWC .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (02) :196-201
[4]   Treatment of lupus with corticosteroids [J].
Chatham, WW ;
Kimberly, RP .
LUPUS, 2001, 10 (03) :140-147
[5]  
Dobkin PL, 2001, J RHEUMATOL, V28, P2442
[6]  
Gladman DD, 1996, CLIN EXP RHEUMATOL, V14, P305
[7]  
Gladman DD, 2003, J RHEUMATOL, V30, P1955
[8]   The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey [J].
Gordon, Caroline ;
Isenberg, David ;
Lerstrom, Kirsten ;
Norton, Yvonne ;
Nikai, Enkeleida ;
Pushparajah, Daphnee S. ;
Schneider, Matthias .
RHEUMATOLOGY, 2013, 52 (12) :2292-2301
[9]   Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices [J].
Griffiths, B ;
Mosca, M ;
Gordon, C .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2005, 19 (05) :685-708
[10]   GLUCOCORTICOIDS AND THE RISK FOR INITIATION OF HYPOGLYCEMIC THERAPY [J].
GURWITZ, JH ;
BOHN, RL ;
GLYNN, RJ ;
MONANE, M ;
MOGUN, H ;
AVORN, J .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (01) :97-101